Pegzilarginase

Last updated

Pegzilarginase
Clinical data
Trade names Loargys
Other namesAEB-1102
Routes of
administration 		Intravenous
ATC code
Legal status
Legal status
Identifiers
CAS Number
PubChem SID
DrugBank
UNII
KEGG
Chemical and physical data
Formula C1554H2492N416O463S6
Molar mass 34603.84 g·mol−1

Pegzilarginase, sold under the brand name Loargys, is a medication used for the treatment of hyperargininemia. [1] [2]

Contents

The most common side effects include allergic reactions. [1]

Pegzilarginase was approved for medical use in the European Union in December 2023. [2]

Medical uses

Pegzilarginase is indicated for the treatment of arginase 1 deficiency, also known as hyperargininemia. [1] [2]

Society and culture

In October 2023, the Committee for Medicinal Products for Human Use adopted a positive opinion, recommending the granting of a marketing authorization under exceptional circumstances for the medicinal product Loargys, intended for the treatment of hyperargininemia. [1] The applicant for this medicinal product is Immedica Pharma AB. [1] Pegzilarginase was approved for medical use in the European Union in December 2023. [2]

Brand names

Pegzilarginase is the international nonproprietary name. [3]

Pegzilarginase is sold under the brand name Loargys. [1]

References

  1. 1 2 3 4 5 6 7 "Loargys EPAR". European Medicines Agency. 14 July 2016. Retrieved 26 December 2023. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  2. 1 2 3 4 5 "Loargys Product information". Union Register of medicinal products. 18 December 2023. Retrieved 26 December 2023.
  3. ↑ World Health Organization (2018). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 79". WHO Drug Information. 32 (1). hdl: 10665/330941 .
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.